Loomis Sayles & Co. L P Has $47.27 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Loomis Sayles & Co. L P cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 2.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,516,123 shares of the specialty pharmaceutical company's stock after selling 40,038 shares during the quarter. Loomis Sayles & Co. L P owned approximately 2.75% of Supernus Pharmaceuticals worth $47,273,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its position in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 398 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in Supernus Pharmaceuticals in the 1st quarter worth approximately $43,000. Meeder Asset Management Inc. acquired a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $47,000. Innealta Capital LLC bought a new position in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after buying an additional 352 shares during the last quarter.

Supernus Pharmaceuticals Trading Up 0.1 %

SUPN stock traded up $0.04 during trading on Tuesday, reaching $36.14. 202,164 shares of the stock were exchanged, compared to its average volume of 443,991. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.37. The company has a market capitalization of $2.00 billion, a P/E ratio of 33.78 and a beta of 0.86. The stock has a 50 day simple moving average of $33.81 and a 200-day simple moving average of $31.14.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. The company had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.29) EPS. Equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Insider Activity

In related news, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares of the company's stock, valued at $487,595.30. This trade represents a 51.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now directly owns 8,200 shares in the company, valued at $303,236. This represents a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 154,213 shares of company stock worth $5,660,180. Corporate insiders own 9.30% of the company's stock.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several recent analyst reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Piper Sandler reaffirmed a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.